BioSpace News Archive

Carestream Health earned the top rating in MD Buyline’s User Satisfaction Ratings for its portable and room-based digital radiography (DR) systems as well as its family of detectors in the first quarter of 2019.

CDRD, Canada’s life sciences venture, TRIUMF, the country’s national particle accelerator centre, and TRIUMF Innovations, the centre’s commercialization arm have joined forces to advance and commercialize promising research in the field of novel radiopharmaceuticals

Acceleron Pharma Inc., a leading biopharmaceutical company in the discovery and development of TGF-beta superfamily therapeutics to treat serious and rare diseases, announced that Robert K. Zeldin, M.D., Chief Medical Officer, is no longer employed by the company

PotNetwork Magazine, the companion magazine to the cannabis sector’s leading news and information website, PotNetwork News, has begun to fill advertising space in the pages of its second print issue, due out in May 2019.

Guardion Health Sciences Inc. (“Guardion”) (Nasdaq:GHSI), today announced the pricing of its initial public offering of 1,250,000 shares of its common stock at a public offering price of $4.00 per share for total gross proceeds of $5.0 million, before deducting underwriting discounts and commissions and other offering costs and expenses payable by Guardion.

Recovery Reform NOW, along with The Opioid Spoon Project (OSP), Prescription Addiction Intervention Now (P.A.I.N.), and Team Sharing, held an action today in front of the Department of Health and Human Services (HHS) in Washington, D.C. where they dropped an 800-pound metal spoon stamped with the logo of the Food and Drug Administration (FDA).

Reston Hospital Center (RHC) and Children’s National Health System in Washington, D.C. announced a strategic partnership to enhance the neonatology services at RHC.

Amyotrophic lateral sclerosis (ALS; a.k.a. Lou Gehrig’s disease) is a motor neuron disease with rampant progression and that it is typically fatal within 5 years of prognosis.

Realm Therapeutics plc announced that the Company received written notice from the Listing Qualifications Staff of The Nasdaq Stock Market LLC indicating that, based upon the Company’s recent Assets Disposal, the Staff believes the Company is a “shell company” and, as such, the continued listing of American Depositary Shares representing the Company’s ordinary shares on Nasdaq is no longer warranted.

Curis, Inc. announced that on April 2, 2019, the independent Compensation Committee of the Board of Directors of Curis approved the grant of inducement stock options to purchase 150,000 shares of Curis common stock to a new employee, with a grant date of April 2, 2019.